Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Actuate Therapeutics IncNASDAQ: ACTU
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 23.54M shares rose 20.7% year over year, ahead of the +12.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.
Context
- Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +20.7% holds above the trailing-twelve-month pace of +12.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 21.02M USD
- Year-over-year change
- +7.7%
- 3-year CAGR
- +11.8%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.02M | +7.7% |
| FY2024 | 2024-12-31 | 19.51M | +29.8% |
| FY2023 | 2023-12-31 | 15.03M | +0.0% |
| FY2022 | 2022-12-31 | 15.03M | — |
Weighted Avg Shares (Diluted) vs competitors
How ACTU compares with its peers on the latest reported figures
- ACTU's LTM Mar 2026 weighted avg shares (diluted) of 21.96M shares is the 6th highest of the 9 companies compared; the peer median is 37.46M shares.
- Its year-over-year change of +12.5% is the 4th highest of 9, against a peer median of +9.7%.
- Over three fiscal years its annual growth of +11.8% compares with a peer median of +18.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 104.14M | +6.5% | +7.7% | |
| LTM Mar 2026 | 74.08M | +0.6% | +19.3% | |
| LTM Mar 2026 | 57.24M | +5.3% | +16.2% | |
| LTM Mar 2026 | 37.49M | +15.0% | +39.2% | |
| LTM Mar 2026 | 37.43M | +9.0% | +3.9% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | 21.96M | +12.5% | +11.8% |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | 16.57M | +32.5% | +70.3% |
| LTM Mar 2026 | 8.99M | +10.4% | +18.0% | |
| LTM Mar 2026 | 5.81M | +40.8% | +70.9% | |
| Peer median (excluding ACTU) | 37.46M | +9.7% | +18.6% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 16.39M | 21.71M | 18.68M | 10.29M |
| Selling, General & Admin | 3.82M | 3.27M | 6.48M | 12.2M |
| Operating Expenses | 20.21M | 24.97M | 25.16M | 22.5M |
| Depreciation & Amortization | 63.61K | 272.85K | 2.14M | 0 |
| EBITDA | (20.08M) | (24.43M) | (25.16M) | (22.21M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (20.21M) | (24.97M) | (25.16M) | (22.5M) |
| Operating Margin | — | — | — | — |
| Interest Income | 27.03K | 352.67K | 222.29K | 287.71K |
| Interest Expense | 16.2K | 43.64K | (18.72K) | 20.25K |
| Other Income / Expenses | 47.41K | 229.21K | (2.12M) | 267.46K |
| Income Before Tax | (20.16M) | (24.74M) | (27.28M) | (22.23M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 800 | 0 |
| Net Income | (20.16M) | (24.74M) | (27.29M) | (22.23M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (1.34) | (1.65) | (3.26) | (1.06) |
| EPS (Diluted) | (1.34) | (1.65) | (3.26) | (1.06) |
| Weighted Avg Shares | 15.03M | 15.03M | 19.51M | 21.02M |
| Weighted Avg Shares (Diluted) | 15.03M | 15.03M | 19.51M | 21.02M |
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.